255 related articles for article (PubMed ID: 11654595)
1. Calls for strengthened drug-trial guidelines in Japan.
Netley G
Lancet; 1997 Feb; 349(9051):552. PubMed ID: 11654595
[No Abstract] [Full Text] [Related]
2. American guidance for institutional review boards.
Bull Med Ethics; 1998 Nov; No. 143():20-4. PubMed ID: 11657619
[No Abstract] [Full Text] [Related]
3. Informed consent in psychiatric research.
Roth LH; Appelbaum PS; Lidz CW; Benson P; Winslade WJ
Rutgers Law Rev; 1987; 39(2-3):425-41. PubMed ID: 11659013
[No Abstract] [Full Text] [Related]
4. Medical Research Involving Human Subjects Act.
Netherlands
Bull Med Ethics; 1999 Nov; No. 152():13-8. PubMed ID: 11658081
[No Abstract] [Full Text] [Related]
5. Money is putting people at risk in biomedical research.
Andrews LB
Chron High Educ; 2000 Mar; 46(27):B1, B4-5. PubMed ID: 11657699
[No Abstract] [Full Text] [Related]
6. Guidelines for addressing ethical and legal issues in Alzheimer disease research: a position paper.
High DM; Whitehouse PJ; Post SG; Berg L
Alzheimer Dis Assoc Disord; 1994; 8(Suppl. 4):66-74. PubMed ID: 11657676
[No Abstract] [Full Text] [Related]
7. Health Sciences Council of Japan adopts guidelines for gene therapy clinical research.
Int Dig Health Legis; 1995; 46(4):560-3. PubMed ID: 11657358
[No Abstract] [Full Text] [Related]
8. New York seeks to tighten rules on medical research.
Rosenthal E
N Y Times Web; 1996 Sep; ():B4. PubMed ID: 11648036
[No Abstract] [Full Text] [Related]
9. Conflict of interest in human research ethics.
Jones DJ
NCBHR Commun; 1995; 6(2):5-10. PubMed ID: 11654611
[No Abstract] [Full Text] [Related]
10. The case for per patient payments.
Lewis JP
IRB; 1988; 10(5):9. PubMed ID: 11650075
[No Abstract] [Full Text] [Related]
11. Why I oppose drug company payment of physician/investigators on a per patient/subject basis.
Roizen R
IRB; 1988; 10(1):9-10. PubMed ID: 11658990
[No Abstract] [Full Text] [Related]
12. Gene therapy in mental retardation: ethical considerations.
Fletcher JC
Ment Retard Dev Disabil Res Rev; 1995; 1():7-13. PubMed ID: 11660293
[No Abstract] [Full Text] [Related]
13. Drug makers relied on clinical researchers who now await trial.
Stecklow S; Johannes L
Wall St J (East Ed); 1997 Aug; ():A1, A6. PubMed ID: 11647688
[No Abstract] [Full Text] [Related]
14. Surrogate consent and the incompetent experimental subject.
Bein PM
Food Drug Cosmet Law J; 1991 Sep; 46(5):739-71. PubMed ID: 11651381
[No Abstract] [Full Text] [Related]
15. Medical research and Alzheimer's disease: a study of the hazards of conducting research on the incompetent patient.
Moodie P; Wright M
Med Law Int; 1997; 2(4):291-313. PubMed ID: 11657578
[No Abstract] [Full Text] [Related]
16. Informed consent in human experimentation: bridging the gap between ethical thought and current practice.
Delgado R; Leskovac H
UCLA Law Rev; 1986 Oct; 34(1):67-130. PubMed ID: 11659049
[No Abstract] [Full Text] [Related]
17. IRB review of a Phase II randomized clinical trial involving incompetent patients suffering from severe closed head injury.
Prentice ED; Antonson DL; Leibrock LG; Kelso TK; Sears TD
IRB; 1993; 15(5):1-7. PubMed ID: 11659703
[No Abstract] [Full Text] [Related]
18. Standards of accountability for consent in research.
Rubenstein LS
Account Res; 1996; 4(3-4):197-206. PubMed ID: 11654515
[No Abstract] [Full Text] [Related]
19. Is post-marketing drug follow-up research or advertising?
Weiss GB; Winslade WJ
IRB; 1987; 9(4):10-1. PubMed ID: 11649947
[No Abstract] [Full Text] [Related]
20. An IRB member's perspective on access to innovative therapy.
Moore DL
Albany Law Rev; 1994; 57(3):559-81. PubMed ID: 11652854
[No Abstract] [Full Text] [Related]
[Next] [New Search]
